ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,199.50
      -0.77%
      US Tech 100
      17,239.60
      -1.94%
      Dow Jones
      38,763.45
      -0.60%
      Brent Oil
      78.385
      0.01%
      Bitcoin
      55,263.32
      0.42%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. IDEAYA Biosciences Inc (IDYA)

      7. IDEAYA Biosciences Inc (IDYA) News

      IDYA

      IDEAYA Biosciences (IDYA)

      IDEAYA Biosciences Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:IDYA
      DateTimeSourceHeadlineSymbolCompany
      08/06/20245:08PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IDYAIDEAYA Biosciences Inc
      08/06/20244:13PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IDYAIDEAYA Biosciences Inc
      08/06/20246:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
      08/06/20246:00AMPR Newswire (US)IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
      07/31/20247:56PMBusiness Wire百奧賽圖宣布與IDEAYA Biosciences就具有同類首創潛力的B7H3/PTK7拓撲異構酶抑制劑有效負載雙特異性ADC專案達成選擇權和授權合約NASDAQ:IDYAIDEAYA Biosciences Inc
      07/31/20246:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
      07/31/20246:00AMBusiness Wire百奥赛图宣布与IDEAYA Biosciences就具有同类首创潜力的B7H3/PTK7拓扑异构酶抑制剂有效载荷双特异性ADC项目达成选择权和许可协议NASDAQ:IDYAIDEAYA Biosciences Inc
      07/31/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with BiocytogenNASDAQ:IDYAIDEAYA Biosciences Inc
      07/31/20246:00AMBusiness WireBiocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC ProgramNASDAQ:IDYAIDEAYA Biosciences Inc
      07/31/20246:00AMBusiness WireBiocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC ProgramNASDAQ:IDYAIDEAYA Biosciences Inc
      07/29/20246:00AMPR Newswire (US)IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations EventNASDAQ:IDYAIDEAYA Biosciences Inc
      07/11/20244:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
      07/11/20244:05PMPR Newswire (US)IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:IDYAIDEAYA Biosciences Inc
      07/10/20245:17PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IDYAIDEAYA Biosciences Inc
      07/09/202410:26PMPR Newswire (US)IDEAYA Announces Pricing of Public OfferingNASDAQ:IDYAIDEAYA Biosciences Inc
      07/09/20245:08PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IDYAIDEAYA Biosciences Inc
      07/09/20244:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
      07/09/20244:08PMPR Newswire (US)IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:IDYAIDEAYA Biosciences Inc
      07/08/20246:37AMIH Market NewsParamount-Skydance $28B Merger, Boeing Agrees to Plead Guilty with $243.6M Fine, and More NewsNASDAQ:IDYAIDEAYA Biosciences Inc
      07/08/20246:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
      07/08/20246:00AMPR Newswire (US)IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung CancerNASDAQ:IDYAIDEAYA Biosciences Inc
      07/05/20244:05PMPR Newswire (US)IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
      06/28/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
      06/25/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder CancerNASDAQ:IDYAIDEAYA Biosciences Inc
      06/24/20246:00AMPR Newswire (US)IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
      06/03/20246:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
      06/03/20246:00AMPR Newswire (US)IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant StudyNASDAQ:IDYAIDEAYA Biosciences Inc
      05/31/20244:54PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
      05/31/20244:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
      05/31/20244:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
       Showing the most relevant articles for your search:NASDAQ:IDYA